PCSK9 inhibitors × lipids

TrialDiabetes, obesity & metabolism2018

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.

Kausik K Ray et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 821 people · 2018

No range given

Reported lower lipids, no range given

−27.0

As reported

difference −27.0, no interval

One number in the abstract

the abstract, start to end

UC, 97.5% confidence interval -38.1 to -27.0; P < .0001).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Lipids
−27.0
PCSK9 inhibitorsLipids
1 / 3

47 papers cite it

2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 29436756